Oštećenje sluha je heterogeno stanje sa preko 40 opisanih lokusa. Protein koji je kodiran ovim genom eksprimiran je u fetusnoj pužnici, međutim, njegova funkcija nije poznata. Sa mutacijom ovog gena povezano je nesindromsko oštećenje sluha.[7]
Opažanje da je DFNA5 epigenetički inaktiviran u velikom broju karcinoma čestih tipova (želuca, debelog crijeva i dojke) je još jedan važan nalaz i u skladu je s njegovim svojstvima koja induciraju apoptozu. Zaista, ako je apoptoza unutrašnja karakteristika DFNA5, gašenje gena u tumorskim ćelijama čini ih podložnijim nekontroliranom ćelijskom rastu. Štaviše, činjenica da je DFNA5 reguliran putem P53 snažno sugerira da je DFNA5 gen supresor tumora.[8]
^"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^"Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^van Camp G, Coucke P, Balemans W, van Velzen D, van de Bilt C, van Laer L, Smith RJ, Fukushima K, Padberg GW, Frants RR (Mar 1996). "Localization of a gene for non-syndromic hearing loss (DFNA5) to chromosome 7p15". Hum Mol Genet. 4 (11): 2159–63. doi:10.1093/hmg/4.11.2159. hdl:2066/20568. PMID8589696.
^Van Laer L, Van Camp G, van Zuijlen D, Green ED, Verstreken M, Schatteman I, Van de Heyning P, Balemans W, Coucke P, Greinwald JH, Smith RJ, Huizing E, Willems P (Mar 1998). "Refined mapping of a gene for autosomal dominant progressive sensorineural hearing loss (DFNA5) to a 2-cM region, and exclusion of a candidate gene that is expressed in the cochlea". Eur J Hum Genet. 5 (6): 397–405. doi:10.1159/000484798. PMID9450185.
Thompson DA, Weigel RJ (1998). "Characterization of a gene that is inversely correlated with estrogen receptor expression (ICERE-1) in breast carcinomas". Eur. J. Biochem. 252 (1): 169–77. doi:10.1046/j.1432-1327.1998.2520169.x. PMID9523727.
Van Laer L, Huizing EH, Verstreken M, van Zuijlen D, Wauters JG, Bossuyt PJ, Van de Heyning P, McGuirt WT, Smith RJ, Willems PJ, Legan PK, Richardson GP, Van Camp G (1998). "Nonsyndromic hearing impairment is associated with a mutation in DFNA5". Nat. Genet. 20 (2): 194–7. doi:10.1038/2503. PMID9771715. S2CID23534085.
Yu C, Meng X, Zhang S, Zhao G, Hu L, Kong X (2004). "A 3-nucleotide deletion in the polypyrimidine tract of intron 7 of the DFNA5 gene causes nonsyndromic hearing impairment in a Chinese family". Genomics. 82 (5): 575–9. doi:10.1016/S0888-7543(03)00175-7. PMID14559215.
Bischoff AM, Luijendijk MW, Huygen PL, van Duijnhoven G, De Leenheer EM, Oudesluijs GG, Van Laer L, Cremers FP, Cremers CW, Kremer H (2004). "A novel mutation identified in the DFNA5 gene in a Dutch family: a clinical and genetic evaluation". Audiol. Neurootol. 9 (1): 34–46. doi:10.1159/000074185. PMID14676472. S2CID20139112.
Van Laer L, Meyer NC, Malekpour M, Riazalhosseini Y, Moghannibashi M, Kahrizi K, Vandevelde A, Alasti F, Najmabadi H, Van Camp G, Smith RJ (2007). "A novel DFNA5 mutation does not cause hearing loss in an Iranian family". J. Hum. Genet. 52 (6): 549–52. doi:10.1007/s10038-007-0137-2. PMID17427029. S2CID24786210.
